ACADIA Pharmaceuticals Holds Successful 2024 Annual Meeting
Company Announcements

ACADIA Pharmaceuticals Holds Successful 2024 Annual Meeting

ACADIA Pharmaceuticals (ACAD) has provided an announcement.

Acadia Pharmaceuticals Inc. successfully conducted its 2024 Annual Meeting on May 29, where stockholders elected three Class II directors to its Board, set to serve until the 2027 Annual Meeting. Additionally, the compensation of the company’s named executive officers was approved, as was the Plan presented during the meeting. Moreover, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Each decision was made with an overwhelming majority of votes in favor.

See more data about ACAD stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAcadia Pharmaceuticals price target lowered to $28 from $30 at Morgan Stanley
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyAcadia Pharmaceuticals initiated with an Outperform at BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!